Behçet Disease With Vascular Involvement
Autor: | Alibaz-Oner, Fatma, Karadeniz, Aslı, Yılmaz, Sema, Balkarlı, Ayşe, Kimyon, Gezmiş, Yazıcı, Ayten, Çınar, Muhammet, Yılmaz, Sedat, Yıldız, Fatih, Bilge, Şule Yaşar, Bilgin, Emre, Coskun, Belkis Nihan, Omma, Ahmet, Çetin, Gözde Yıldırım, Çağatay, Yonca, Karaaslan, Yaşar, Sayarlıoğlu, Mehmet, Pehlivan, Yavuz, Kalyoncu, Umut, Karadağ, Ömer, Kaşifoğlu, Timuçin, Erken, Eren, Pay, Salih, Çefle, Ayşe, Kısacık, Bünyamin, Onat, Ahmet Mesut, Çobankara, Veli, Direskeneli, Haner |
---|---|
Přispěvatelé: | İç Hastalıkları |
Jazyk: | angličtina |
Rok vydání: | 2015 |
Předmět: | |
Zdroj: | Medicine |
ISSN: | 1536-5964 0025-7974 |
Popis: | Vascular involvement is one of the major causes of mortality and morbidity in Behçet disease (BD). There are no controlled studies for the management of vascular BD (VBD), and according to the EULAR recommendations, only immunosuppressive (IS) agents are recommended. In this study, we aimed to investigate the therapeutic approaches chosen by Turkish physicians during the initial event and relapses of VBD and the association of different treatment options with the relapses retrospectively. Patients with BD (n = 936, female/male: 347/589, mean age: 37.6 ± 10.8) classified according to ISG criteria from 15 rheumatology centers in Turkey were included. The demographic data, clinical characteristics of the first vascular event and relapses, treatment protocols, and data about complications were acquired. VBD was observed in 27.7% (n = 260) of the patients during follow-up. In 57.3% of the VBD patients, vascular involvement was the presenting sign of the disease. After the first vascular event, ISs were given to 88.8% and AC treatment to 59.8% of the patients. Median duration of AC treatment was 13 months (1–204) and ISs, 22 months (1–204). Minor hemorrhage related to AC treatment was observed in 7 (4.7%) patients. A second vascular event developed in 32.9% (n = 86) of the patients. The vascular relapse rate was similar between patients taking only ISs and AC plus IS treatments after the first vascular event (29.1% vs 22.4%, P = 0.28) and was significantly higher in group taking only ACs than taking only ISs (91.6% vs 29.1%, P |
Databáze: | OpenAIRE |
Externí odkaz: |